STOCK TITAN

Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vera Therapeutics director Scott W. Morrison received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, or sooner upon a change in control, subject to his continued service. After this grant, he holds options on 17,084 shares directly.

Positive

  • None.

Negative

  • None.
Insider Morrison Scott W
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 17,084 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 17,084 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 17,084 shares Stock options on Class A common stock granted to director
Exercise price $34.35 per share Strike price of newly granted stock options
Post-grant derivative holdings 17,084 derivative securities Total options held following the transaction
Option expiration May 20, 2036 Expiration date of the stock option award
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
change in control financial
"the shares will vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
annual stockholder meeting financial
"the date of the Company's 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
vesting financial
"The shares subject to the option will vest in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morrison Scott W

(Last)(First)(Middle)
C/O VERA THERAPEUTICS, INC.
2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$34.3505/21/2026A17,084 (1)05/20/2036Class A Common Stock17,084$017,084D
Explanation of Responses:
1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
/s/ Joseph R. Young, Attorney-in-Fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Vera Therapeutics (VERA) disclose about Scott W. Morrison’s recent equity grant?

Vera Therapeutics reported that director Scott W. Morrison received a stock option grant for 17,084 shares of Class A common stock. The options were awarded as compensation and are exercisable at $34.35 per share, subject to specific vesting conditions tied to time and corporate events.

How many Vera Therapeutics (VERA) shares are covered by Scott W. Morrison’s new stock options?

The new stock option grant to Scott W. Morrison covers 17,084 shares of Vera Therapeutics Class A common stock. These options represent his entire position reported in this filing, with 17,084 derivative securities held directly following the grant, according to the disclosed totals.

What is the exercise price of Scott W. Morrison’s Vera Therapeutics (VERA) stock options?

The stock options granted to Scott W. Morrison have an exercise price of $34.35 per share. This means he can purchase Vera Therapeutics Class A common stock at $34.35 once the options are vested and exercisable, subject to the grant’s vesting schedule and expiration date in 2036.

When do Scott W. Morrison’s Vera Therapeutics (VERA) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics’ 2027 annual stockholder meeting. Vesting is contingent on Morrison’s continuous service with the company through that date, as specified in the grant terms.

What happens to Scott W. Morrison’s Vera Therapeutics (VERA) options if there is a change in control?

If Vera Therapeutics undergoes a change in control, Scott W. Morrison’s options will vest in full on that date. This accelerated vesting is conditioned on his continuous service with the company through the change-in-control date, according to the footnote describing the award’s terms.

Are Scott W. Morrison’s Vera Therapeutics (VERA) options an open-market stock purchase?

No, the transaction is a grant of stock options as compensation, not an open-market stock purchase. The Form 4 describes it with transaction code A, indicating an award or other acquisition, with no cash price paid at grant and vesting based on service conditions.